Table 1.
Studies on NAC response with original RNA subtyping data.
| Study | n, NAC + RNA Data | Regimen | k Subtypes, Classifier | Response Criteria | Response | Survival Post-NAC |
|---|---|---|---|---|---|---|
| Choi et al. [32] | 100 | MVAC | 3, MDA | pT0 or pT1 1 | ↑Lum, Basal ↓p53-like |
N.S. ↑Lum ↓p53-like |
| McConkey et al. [33] | 38 | 4 MVAC + Bev | 3, MDA | <pT2 | N.S. ↓p53-like | ↑Basal ↓p53-like |
| Seiler et al. [34] | 251 | ≥3 MVAC GC | 4, GSC | pT < 2 N0 | N.S. ↑Lum | ↑Basal, Lum ↓Lum-inf, Claudin-low |
| Taber et al. [20] | 44 | GC | 6, Consensus | ≤pTa, cis,N0 | ↑Stroma-rich ↓Ba/Sq | ↓Ba/Sq |
| Lotan et al. [35] | 247 2 | Cisplatin-based | 4, GSC | Not reported | Not reported | ↓NAC benefit Lum |
| Sjödahl et al. [36] | 125 | ≥2 MVAC GC | 7, LundTax | pT0N0 | ↑GU ↓Ba/Sq | ↑Lum (GU, UroC) ↓Ba/Sq |
| Lerner et al. abstract [37] |
161 | 4 MVAC GC | 3, Consensus; 3, TCGA; 3, MDA | pT0 | N.S. | Not reported |
1 pT1 was counted as a response only for patients who fulfilled certain high-risk criteria. 2 82 of the NAC-treated patients overlapped with the study by Seiler et al. Abbreviations: NAC, neoadjuvant chemotherapy; MVAC, metotrexate vinblastine adriamycin and cisplatin; Bev, bevacizumab; GC, gemcitabine and cisplatin; MDA, MD-Anderson; GSC, genomic subtype classifier; LundTax, Lund taxonomy; TCGA, the cancer genome atlas; pT, pathological T-stage; cis, carcinoma in situ; Lum, Luminal; Ba/Sq, basal/squamous; GU, genomically unstable; N.S., not significant; UroC, urothelial-like C.